These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 31725440)

  • 1. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
    Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
    Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toxicities of immune checkpoint inhibitors and their management].
    Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
    Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses.
    Chhabra N; Kennedy J
    J Med Toxicol; 2022 Jan; 18(1):43-55. PubMed ID: 33821435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
    Chhabra N; Kennedy J
    J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1.
    Brigida M; Perricelli A; Sposato F; Spadafora MG; Pomillo A; Sisto M
    Rev Recent Clin Trials; 2020; 15(4):339-346. PubMed ID: 32568023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].
    Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
    Ragoonanan D; Khazal SJ; Abdel-Azim H; McCall D; Cuglievan B; Tambaro FP; Ahmad AH; Rowan CM; Gutierrez C; Schadler K; Li S; Di Nardo M; Chi L; Gulbis AM; Shoberu B; Mireles ME; McArthur J; Kapoor N; Miller J; Fitzgerald JC; Tewari P; Petropoulos D; Gill JB; Duncan CN; Lehmann LE; Hingorani S; Angelo JR; Swinford RD; Steiner ME; Hernandez Tejada FN; Martin PL; Auletta J; Choi SW; Bajwa R; Dailey Garnes N; Kebriaei P; Rezvani K; Wierda WG; Neelapu SS; Shpall EJ; Corbacioglu S; Mahadeo KM
    Nat Rev Clin Oncol; 2021 Jul; 18(7):435-453. PubMed ID: 33608690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
    Cazzaniga ME; Danesi R; Girmenia C; Invernizzi P; Elvevi A; Uguccioni M;
    Breast Cancer Res Treat; 2019 Aug; 176(3):483-494. PubMed ID: 31065872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician.
    Lomax AJ; McNeil C
    Emerg Med Australas; 2017 Apr; 29(2):245-251. PubMed ID: 28093870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity associated with immunotherapy of cancer.
    Amos SM; Duong CP; Westwood JA; Ritchie DS; Junghans RP; Darcy PK; Kershaw MH
    Blood; 2011 Jul; 118(3):499-509. PubMed ID: 21531979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy and the management of side effects.
    Mahalingam P; Newsom-Davis T
    Clin Med (Lond); 2023 Jan; 23(1):56-60. PubMed ID: 36697001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events.
    Aggarwal S
    Indian J Cancer; 2019 Nov; 56(Supplement):S10-S22. PubMed ID: 31793438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
    Cook J; Litzow M
    Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
    Kottschade L; Brys A; Peikert T; Ryder M; Raffals L; Brewer J; Mosca P; Markovic S;
    Melanoma Res; 2016 Oct; 26(5):469-80. PubMed ID: 27306502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.